UPMC Physician Resources

UPMC Heart and Vascular Experts Present at the American Heart Association’s Annual Scientific Sessions

The UPMC Heart and Vascular Institute was well-represented at the American Heart Association’s Scientific Sessions in Anaheim, CA on Saturday, Nov. 11 – Wednesday, Nov. 15. Faculty research was presented in both oral and abstract presentations including:

Saturday, November 11, 2017

Session RESS.CVS.02 – Main Event: Outcomes of Cardiac Arrest Survivors With ICDs

Rehabilitation for Cardiac Arrest Survivors with ICDs

Presented by: Jon C. Rittenberger

 

Session RESS.CVS.06 – Main Event: Prognostication After Resuscitation

Prognostication After Major Trauma and TBI

Presented by: Lori A. Shutter

 

Sunday, November 12, 2017

Session SA.JS.783 – Innovation in Cardiac Surgery: From Imaginative Research to Transformative Clinical Therapy (AHA/The Society of Thoracic Surgeons Joint Session)

Should Bicuspid Valves Ever Be Repaired?

Presented by: Thomas Gleason

 

Session QU.APS.01 – Quality of Care: Acute and Chronic CAD

Predictors of Emergency Medical Personnel’s Decision to Transmit or Not to Transmit the Prehospital 12-Lead ECG of Patients With Suspected Acute Myocardial Infarction

Presented by: Amber DeSantis, Parker Landis, Mohammad Alrawashdeh, Christian Martin-Gill, Clifton Callaway, Salah S Al-Zaiti

 

Session NR.APS.02 – Monitoring and ICDs: Patients With ACS and CABG

The Prevalence of Secondary Repolarization Abnormalities  Confounding the Electrocardiographic Diagnosis of Acute Myocardial Ischemia in Patients Presenting With Chest Pain

Presented by: Diana Rivero, Mohammad Alhamaydeh, Christian Martin-Gill, Clifton Callaway, Barbara Drew, Salah S Al-Zaiti

 

Time of Day and Day of Week Variations in Chest Pain Encounters at the Prehospital Setting

Presented by: Mohammad Alhamaydeh, Mohammad Alrawashdeh, Christian Martin-Gill, Clifton Callaway, Salah S Al-Zaiti

Incidence and Predictors of Delaying Seeking Emergent Medical Care Among Patients With Suspected Acute Coronary Syndrome

Presented by: Stephanie Frisch, Christian Martin-Gill, Mohammed Alrawashdeh, Clifton Callaway, Salah Al-Zaiti

 

Session CH.APS.01 – Fetal Cardiology

Fetal Hemodynamics Predict Postnatal Regional and Microstructural Brain Alterations in Complex Congenital Heart Disease

Presented by: Jodie K. Votava-Smith, Jay D. Pruetz, Nhu Tran, Vincent Lee, Hollie Lai, Vincent J. Schmithorst, Lisa B. Paquette, Ashok Panigrahy

 

Session CH.RFO.03 – Transitional Research in CHD

Altered Placental Bold Signal is Associated With Reduced Fetal Brain Functional Connectivity in Congenital Heart Disease

Presented by: Vidya Rajagopalan, Vincent K Lee, William Reynolds III, Alex El-Ali, Jenna Schabdach, Julia Wallace, Alexandria Zahner, Rafael Ceschin, Jodie Votava-Smith, Jacqueline Weinberg, Vincent J Schmithorst, Ashok Panigrahy

 

Session HF.APS.08 – Heart Failure and Cardiomyopathies: General Topics IIII

Are Echocardiogram and Magnetic Resonance Imaging (MRI) Comparable in Measuring Maximal Septal Thickness in Children With Hypertrophic Cardiomyopathy (HCM)?

Presented by: Sonya Kirmani, Pamela K Woodard, Ling Shi, Charles E Canter, Steven D Colan, Elfriede Pahl, Jeffrey A Towbin, Steven A Webber, Joseph W Rossano, Melanie D Everitt, Kimberly M Molina, Paul F Kantor, John L Jefferies, Brian Feingold, Linda J Addonizio, Stephanie M Ware, Wendy K Chung, Jean A Ballweg, Teresa M Lee, Hiedy Razoky, Jason D Czachor, Fatima I Lunze, Edward Marcus, James D Wilkinson, Steven E Lipshultz

 

Session CH.RFO.03 – Translational Research in CHD

Identification of a Novel TPM1 Mutation in Congential Atrial Septal Defect With Autosomal Dominant Inheritance

Presented by: Polakit Teekakirikul, Wenjuan Zhu, Michael X Wang, Amanda M Smith, Honglan Gou, Abha Bais, Omar Khalifa, Maliha Zahid, Stephanie M Ware, Brian Feingold, Cecilia W Lo

 

 

Session IN.APS.05 – Percutaneous Non-Coronary Cardiac Intervention

Denovo Pulmonary Hypertension After Transcatheter Aortic Valve Replacement is Associated With Higher Mortality – The Importance of Continued Assessment

Presented by: Joao L Cavalcante, Islam Abdelkarim, Jeffrey Xu, Michael Sharbaugh, Andrew D Althouse, Dustin Kliner, Ibrahim Sultan, Frederick Crock, Matthew E Harinstein, William E Katz, Joon S Lee, John T Schindler, Thomas G Gleason

 

Session RESS.AOS.11A – Oral Abstracts-Cardiac Arrest Epidemiology

Long-Term Outcomes Disparities in Survivors of Cardiac Arrest 

Presented by: Patrick J Coppler, Jonathan Elmer, Jon C Rittenberger, Clifton W Callaway, David J Wallace

 

Session Va.APS.01 – Latest in Pulmonary Embolism, Injury and Non Group 1 Pulmonary Hypertension

Effect of Remodulin in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Presented by: Jian Hu, Ana L Mora, Mark T Gladwin, Yen-Chun Charly Lai

 

Monday, November 13, 2017

Session SA.APS.05 – Thoracic Aortic Surgery II

Characterization of Type B Acute Aortic Dissection Patients With Presenting Spinal Cord Ischemia

Presented by: Jonathan Silverberg, Thomas G Gleason, Maral Ouzounian, Reed E Pyeritz, Marek P Ehrlich, Takeyoshi Ota, Eduardo Bossone, Stuart Hutchison, Truls Myrmel, Mark D Peterson, Gilbert R Upchurch Jr, Daniel G Montgomery, Eric M Isselbacher, Christoph A Nienaber, Kim A Eagle, Himanshu J Patel

 

Session GE.APS.03 – Genetics and Genomics Using Big Data

GWAS Identifies GPC6 as a Novel Predictor of Arrhythmia in Heart Failure

Presented by: Haider Mehdi, Ryan L Boudreau, Rebecca Gutmann, Patrick Breheny, Gina M Morgan, Alexander M Greiner, Heather L Bloom, Alaa Shalaby, Raul Weiss, Samuel C Dudley, Samir Saba, Dennis M McNamara, Madhurmeet Singh, Steven A Lubitz, Patrick T Ellinor, Barry London

 

 

Session VA.AOS.1970 – Not Home Alone: Mechanistic Insights into Associated Pulmonary Hypertension

Proinflammatory Monocytes and Fibrotic Alveolar Macrophages Are Associated With Progression of Pulmonary Arterial Hypertension in a Primate Model of Human Immunodeficiency Virus Infection

Presented by: Finja Schweitzer, Rebecca Tarantelli, Marc Simon, Whitney Rabacal, Emily Rayens, Karen Norris

 

Session AT.APS.22 – Vascular Science and Hypertension: Experimental

Longitudinal Assessment of Hemodynamic Changes in a NonHuman Primate Model of Human Immunodeficiency Virus Associated Pulmonary Arterial Hypertension

Presented by: Rebecca A Tarantelli, Marc A Simon, Rebecca Vanderpool, Ian Christman, Finja Schweitzer, Heather Kling, Toni Ann Zullo, Eoin J Carney, Brian Lopresti, Karen A Norris

 

Session HF.APS.18 – CHF/Cardiomyopathy: Novel Insights

NAT2 Genotype and Outcomes in the Genetic Sub-Study of the African American Heart Failure Trial (AHeFT)

Presented by: Barry E Bleske, Hao-Jie Zhu, Karen Hanley-Yanez, Indrani Halder, Dennis M McNamara

 

Session RESS.APS.03.07 – ReSS Poster Session Day 3, Section 07

Clinical Outcomes and Mortality Impact of Hyperbaric Oxygen Therapy in Patients With Carbon Monoxide Poisoning

Presented by: Jason J Rose, Seyed M Nouraie, Marc C Gauthier, Anthony F Pizon, Melissa I Saul, Michael P Donahoe, Mark T Gladwin

 

Session RESS.APS.03.13 – ReSS Poster Session Day 3, Section 13

Hypothermic to Ischemic Ratio as a Predictor of Good Functional Outcome From Out-of-Hospital Cardiac Arrest in the Resuscitation Outcomes Consortium Amiodarone Lidocaine or Placebo Study

Presented by: Kelly N Sawyer, Andrew Humbert, Brian G Leroux, Graham Nichol, Peter J Kudenchuck, Mohamud R Daya, Brian Grunau, Henry E Wang, Joseph P Ornato, Jon C Rittenberger, Tom P Aufderheide, Lynn Wittwer, M Riccardo Colella, Michael Austin, Takahisa Kawano, Debra Egan, Neal Richmond, Veer D Vithalani, Damon Scales, Andrew J Baker, Laurie J Morrison, Michael C Kurz

 

Session RESS.APS.03.11 – ReSS Poster Session Day 3, Section 11

Times to Recovery in Individual Domains of the Cerebral Performance Category-Extended

Presented by: Katharyn L Flickinger, Melissa J Repine, Allison C Koller, Margo B Holm, Elizabeth R Skidmore, Clifton W Callaway, Jon C Rittenberger

 

Session RESS.APS.03.13 – ReSS Poster Session Day 3, Section 13

Delayed Left Atrial Decompression is Associated With Prolonged Duration of Veno-arterial Extracorporeal Membrane Oxygenation Support: Results of a Multicenter Pediatric Interventional Cardiology Early Career Society (PICES) Study

Presented by: Jeffrey D. Zampi, Fares Alghanem, Sunkyung Yu, Ryan Callahan, Christopher L. Curzon, Jeffrey W. Delaney, Robert G. Gray, Carrie E. Herbert, Ryan A. Leahy, Ray Lowery, Sara K. Pasquali, Priti M. Patel, Diego Porras, Shabana Shahanavaz, Ravi R. Thiagarajan, Sara M. Trucco, Mariel E. Turner, Surendranath R. Veeran Reddy, Shawn C. West, Wendy Whiteside, Bryan H. Goldstein

 

Session RESS.AOS.14 – Dickinson W. Richards Memorial Lecture

Epidemiology of Out-of-Hospital Cardiac Arrest Within the Resuscitation Outcomes Consortium From 2011 to 2015: Improved Survival Though Site Differences Persist

Presented by: Dana M Zive, Robert Schmicker, Mohamud Daya, Peter Kudenchuk, Jon C Rittenberger, Tom Aufderheide, Gary Vilke, Jim Christenson, Jason Buick, Ken Kaila, Susanne J May, Thomas Rea, Laurie J Morrison

 

Session SA.CVS.762 – Hot Topics in Cardiovascular Surgery

Toward Precision/Molecular Medicine: Determinants of Surgical Decision Making in Bicuspid Valve Disease

Presented by: Thomas Gleason

 

Session LB.APS.09 – Clinical Risk Factors and Biomarkers in Risk Prediction

Evaluating the Diagnostic Accuracy of Clinical Risk Scores to Detect Acute Coronary Syndrome in Patients Evaluated at the Emergency Department for a Chief Complaint of Chest Pain

Presented by: Ziad Faramand, Mohammad Alrawashdeh, Christian Martin-Gill, Clifton Callaway, Salah S Al-Zaiti

 

Session HF.APS.25 – New Insights into Heart Failure Biomarkers

Interaction of G-Protein Beta 3 Subunit (GNB3) and G-Protein Receptor Kinase 5 (GRK5) Genotypes Impacts Heart Failure Outcomes in African Americans

Presented by: Amber E Johnson, Karen Hanley-Yanez, Clyde W Yancy, Anne L Taylor, Arthur M Feldman, Dennis M McNamara

 

Session GE.APS.07 – Genomics of Cardiovascular Risk

Contribution of ABCA1 Genetic Variation to Plasma Lipid Levels in Non-Hispanic White Americans

Presented by: Vipavee Niemsiri, Xingbin Wang, Zaheda H Radwan, Dilek Pirim, Indrani Halder, Steven E Reis,  John E Hokanson, Richard F Hamman, M Michael Barmada, Eleanor Feingold, F Yesim Demirci, M Ilyas Kamboh

 

Session CH.APS.13 – Congenital Heart Disease and Pediatric Cardiology: General Topics

Impaired Pre-Operative Cerebral Autoregulation is Associated With Functional Brain Dysmaturation in Neonatal Congenital Heart Disease

Presented by: Jodie K Votava-Smith, Vincent J. Schmithorst, Nhu Tran, Sadaf Soleymani, Justin Abbott, Vincent Lee, Sylvia del Castillo, Hollie A. Lai, Lisa B. Paquette, Ashok Panigrahy

 

Session EA.RFO.04 – State of the Art: Topical Trial Results From Electrophysiology

Wealth Brings Health: Annual Income is Associated With Health-related Quality of Life in Atrial Fibrilation

Presented by: Emily N Guhl, Andrew D Althouse, Michael Sharbaugh, Courtney L Schlusser, Jared W Magnani  

 

Session HF.APS.16 – Heart Failure and Cardiomyopathies: General Topics IV

Sex Differences and Outcomes of Heart Failure Admissions Stratified by Left Ventricle Ejection Fraction

Presented by: Ahmad Masri, Andrew D Althouse, Gavin Hickey, Jeffrey McKibben, Ravi Ramani, Michael Mathier, Joon Lee, Oscar Marroquin, Suresh Mulukutla

 

Tuesday, November 14, 2017

Session HF.APS.40 – Insights into CHF Risk Factors and Outcomes

Cytokine Elevations and Outcomes in Peripartum Cardiomyopathy

Presented by: Dennis M McNamara, Karen Hanley-Yanez, Penelope Morel, Charles McTiernan

 

Session HF.APS.33 – Novel Insights Into the Diagnosis and Prognosis of Cardiomyopathy and Heart Failure

Cellular Immune Activation and Breastfeeding in Peripartum Cardiomyopathy

Presented by: Agnes Koczo, Amy Marino, Arun Jeyabalan, Uri Elkayam, Leslie Cooper, James Fett, Charles McTiernan, Penelope Morel, Karen Hanley-Yanez, Dennis McNamara

 

Session: IM.CVS.732 – TAVR: Imaging Highlights

Echocardiography Assessment of Critical Aortic Stenosis prior to TAVR

Presented by: Joao L Cavalcante

 

Session ST.AOS.888 – Stroke Oral Abstracts

Biventricular Cardiac Dysfunction in Neurocardiac Injury Assessed by Strain Imaging is Associated With In Hospital Mortality in Subarachnoid Hemorrhage

Presented by: Nobuyuki Kagiyama, Masataka Sugahara, Nina E. Hasselberg, Eliabeth A. Crago, Theodore F. Lagattuta, Khalil Moh’d Yousef, Marilyn T. Hravnak, John Gorcsan III

 

Session IM.APS.19 – Echocardiography: Hypertension, Coronary Artery Disease, and Function

Biventricular Strain as a New Marker of Severity of Neurocardiac Injury in Patients With Subarachnoid Hemorrhage

Presented by: Nobuyuki Kagiyama, Masataka Sugahara, Nina E. Hasselberg, Eliabeth A. Crago, Theodore F. Lagattuta, Khalil Moh’d Yousef, Marilyn Hravnak, John Gorcsan III

 

Session EP.RFO.42 – AHA’s Life Simple 7 and 2020 Goals

The AHA Life Simple 7: An Assessment Using the Behavorial Risk Factor Surveillance System 2011-2015

Presented by: Andrew D Althouse, Michael S Sharbaugh, Floyd W Thoma, Joon Sup Lee, Vince M Figueredo, Suresh R Mulukutla

 

Session CH.CVS.682 – VAD to Transplant: Challenges and Insights

Are we too sensitive? Challenges With managing the Sensitized Patient

Presented by: Brian Feingold

 

Session WS.APS.04 – Race, Sex, SES: Disparities in Cardiovascular Care

African-American Ethnicity, Risk Variables, Coronary Artery Disease, and Long-Term Prognosis in Women: The National Heart, Lung, and Blood Institute Sponsored Women’s Ischemia Syndrome Evaluation Study

Presented by: Pankaj Malhotra, Galen Cook-Wiens, Carl J Pepine, Eileen M Handberg, Steven E Reis, Nathaniel Reichek, Vera Bittner, Sheryl F Kelsey, Reddy Sailaja Marpuri, George Sopko, C Noel Bairey Merz

Stroke Study Expands Window of Clot Removal Treatment for Some Patients

A procedure to remove clots from blocked brain vessels – known as thrombectomy – may be beneficial for some stroke patients even if they come in to the emergency room beyond the 6-hour treatment window that current guidelines endorse, according to a groundbreaking study conducted by an international team of physicians and researchers led by UPMC and Emory University.

The results, which were first announced in May at the European Stroke Organization Conference were published today in the New England Journal of Medicine.

“When the irreversibly damaged brain area affected by the stroke is small, we see that clot removal can make a significant positive difference, even if performed outside the six hour window,” said Tudor Jovin, MD, director, UPMC Stroke Institute, director UPMC Center for Endovascular Therapy and professor of neurology and neurosurgery at the University of Pittsburgh, who co-led the trial. “However, this does not diminish urgency with which patients must be rushed to the ER in the event of a stroke. The mantra ‘time is brain’ still holds true.”

In the study, researchers randomly assigned stroke victims who arrived at the hospital outside the six-hour time window to either thrombectomy or to standard medical therapy. To select patients for the trial, the researchers used a new paradigm, which used brain imaging and clinical criteria as opposed to just time alone.

“Looking at the physiological state of the brain and evaluating the extent of damage and other clinical factors may be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,” said co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine, and director of neuroendovascular service at Marcus Stroke & Neuroscience Center, Grady Memorial Hospital.

Brain imaging and clinical information (neurological deficit) was used to identify and enroll patients who had a small area of irreversibly damaged brain and a significantly larger brain tissue area that was imminently threatened by loss of blood supply, but still alive – a criterion known as clinical infarct mismatch.

The results showed that almost half of the patients (48.6 percent) receiving endovascular therapy had a good outcome at 90 days after treatment – defined as the patient being independent in activities of daily living – showed clinical benefit, while only 13.1 percent showed benefit in the group that received clot-busting drugs alone. There was no difference in mortality between the two groups.

The researchers planned to enroll a maximum of 500 patients over the course of the study period. However, a pre-planned intermediate review of the treatment effectiveness when 200 patients were enrolled led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the selected patients.

The multi-center international study known as the DAWN trial included trial locations in the United States, Spain, France, Australia and Canada. The trial was sponsored by Stryker Corporation, which manufactures the clot removal devices used in the study.

Volker Musahl, MD, named Division Chief of Sports Medicine

Volker Musahl Volker Musahl, MD has been appointed Division Chief of Sports Medicine in the Department of Orthopaedic Surgery at the University of Pittsburgh School of Medicine. Dr. Musahl is currently Medical Director of UPMC Rooney Sports Complex and also serves as Program Director for the Sports Medicine Fellowship Program. He also serves as Co-Head Team Physician for the varsity football program at the University of Pittsburgh.

Dr. Musahl initially came to the Department in 2000 as an Arbeitsgemeinschaft fur Arthroskopie (AGA) Fellow and completed training as an orthopaedic surgery resident in 2008. Following a Sports Medicine/Shoulder Surgery fellowship at Cornell Medical Center in New York, he returned in 2009 as an Assistant Professor, and was promoted to Associate Professor in 2012. He also holds a joint appointment as Associate Professor in the Department of Bioengineering, Swanson School of Engineering. Dr. Musahl is Board-certified by the American Board of Orthopaedic Surgery with subspecialty certification in Orthopaedic Sports Medicine.

Dr. Musahl’s research interests focus on the clinical and basic science of knee and shoulder injuries in athletes. He and Dr. Richard Debski serve as Co-Director of the Orthopaedic Robotics Laboratory, a state-of-the-art robotics laboratory which is the first of its kind in the United States. Dr. Musahl is currently Co-PI in a multi-center trial on anterior cruciate ligament surgery and research with significant funding from the Department of Defense (DOD). He served as Principal Investigator of an international multicenter trial for the study “Clinical Evaluation and Validation of Pivot Shift following ACL-R” with grant support awarded by the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine. He has been extremely successful in attracting external funding, including more than ten grants from the DOD and NIH, as well as support from foundation, industry, and other sources.

“Dr. Musahl demonstrates a strong commitment to education and continues to accept additional teaching responsibilities related to the education and training of medical students, residents, and fellows as well as athletic training students. He leads the sports medicine lecture series curriculum, mentors the clinical fellows in lectures, journal clubs, wet labs, and in the OR, and also conducts weekly shoulder research group meetings. His commitment to education is further evidenced by his mentoring of bioengineering graduate students. Since 2011, Dr. Musahl has served as Associate Team Physician for the varsity football program at the University of Pittsburgh. He also serves as the team physician for the US Soccer (U-14 boys’ national team) and Mt. Lebanon High School.

Dr. Musahl has gained an international reputation as a leader in the field of sports medicine. He is an outstanding clinician, surgeon, teacher, mentor, and researcher, and we are very fortunate to have such an exemplary member of our faculty, ” said Freddie H. Fu, MD, DSc(Hon.), DPs(Hon.), the David Silver Professor and Chairman in the Department of Orthopaedic Surgery at the University of Pittsburgh School of Medicine.

 

 

 

Florida Hospital for Children Partners with Children’s Hospital of Pittsburgh of UPMC to Develop Pediatric Liver Transplant Program in Florida

PrintIn order to make lifesaving liver transplants available throughout central and north Florida, Florida Hospital for Children is partnering with Children’s Hospital of Pittsburgh of UPMC to develop a comprehensive pediatric liver transplant program. This will be the first program of its kind in Orlando, the second in Florida, and is expected to start accepting patients in January.

Florida Hospital is one of the largest not-for-profit hospitals in the country. The organization’s range of nationally and internationally recognized services includes transplant, pediatrics, cardiology and advanced surgical programs. Florida Hospital for Children’s flagship hospital in Orlando is the heart of a children’s network that includes primary care pediatricians, specialty clinics, emergency departments and Kids Urgent Care.

“There is a critical need for children across our state to have access to a liver transplant program that is close to home,” said Regino Gonzalez-Peralta, MD, director of pediatric gastroenterology, hepatology and liver transplantation with Florida Hospital for Children. “This partnership brings the experience of one the nation’s best pediatric liver transplant programs to central Florida. The Florida Hospital and Children’s Hospital of Pittsburgh of UPMC’s partnership is not only a win for our patients, but all of Florida.”

The teams will work in partnership with Florida Hospital’s Transplant Institute, which offers kidney, liver, kidney/pancreas, lung and heart transplants.

“Florida Hospital has been committed to saving lives through our transplant programs for more than 40 years, and it is our goal to provide the same level of advanced and compassionate care to infants and children in our community in need of liver transplants,” said Thomas Chin, MD, director of the Florida Hospital Transplant Institute’s liver transplant program. “We are honored to partner with Children’s Hospital of Pittsburgh of UPMC and bring our world-class programs together.”

In order to offer these transplants to families in the Florida area, the hospital will work with the Hillman Center for Pediatric Transplantation at Children’s Hospital of Pittsburgh of UPMC, which has performed more than 1,800 pediatric liver transplants – more than any other center in the United States, according to the United Network for Organ Sharing, with patient survival rates consistently higher than national averages.

“We are grateful for this opportunity to now expand our services and expertise in pediatric liver transplantation to families in the Florida area,” said George V. Mazariegos, MD, chief of pediatric transplantation at Children’s. “Our extension of expertise will provide the best possible care and make transplant a life-saving treatment for local families and help them to achieve a better quality of life.”

In 1981, Children’s Hospital of Pittsburgh of UPMC opened the country’s first comprehensive pediatric transplant center under the guidance of transplant pioneer Thomas E. Starzl, MD, PhD. According to the 2017 data released by the Scientific Registry of Transplant Recipients, the pediatric liver transplant program at Children’s ranks number 1 out of 62 pediatric liver transplant centers in the United States for one-year overall patient and graft survival when comparing hazard ratio estimates. The program remains at the leading edge of expertise, innovation, and patient- and family centered care for transplant patients from all over the world.

Members of the transplant team from Children’s Hospital of Pittsburgh of UPMC will participate in the management of patients in Florida. Transplant surgeons, medical specialists and nurses from Florida and Children’s Hospital of Pittsburgh of UPMC will perform pediatric liver transplant surgeries together at Florida Hospital for Children.

The pediatric liver transplant partnership with Florida Hospital is the second program of its kind for Children’s Hospital of Pittsburgh of UPMC. In 2016, Children’s Hospital became the first and only pediatric liver transplant program to expand the geographic reach of its expertise through a partnership with the University of Virginia Children’s Hospital in Charlottesville. Today, Children’s pediatric liver transplant network extends from Pittsburgh to Virginia, and now Florida.

UPMC Announces $2B Investment to Build 3 Digitally Based Specialty Hospitals Backed by World-Leading Innovative, Translational Science

New patient-focused cancer, heart and transplant, vision and rehabilitation hospitals augment mental health, pediatric and women’s specialty care

UPMC today announced a bold plan to transform patient care with three leading-edge, new specialty hospitals that will offer next-generation treatments in patient-focused, technology-enhanced settings unique to health care. Backed by a $2 billion investment from UPMC, the all-new UPMC Heart and Transplant Hospital, UPMC Hillman Cancer Hospital and UPMC Vision and Rehabilitation Hospital will add to UPMC’s complement of advanced specialty care at Magee-Womens Hospital, Western Psychiatric Institute and Clinic, and Children’s Hospital of Pittsburgh.

“UPMC is recognized around the world for pioneering treatments that are backed by groundbreaking research in an unparalleled care network,” said Jeffrey A. Romoff, president and chief executive officer, UPMC. “Our transformative vision will make available the most innovative treatments for cancer, heart disease, transplantation, diseases of aging, vision restoration and rehabilitation, among many others. Working in partnership with the University of Pittsburgh Schools of the Health Sciences, we will radically change health care as we know it to provide personalized, effective and compassionate care. At core, these digitally based specialty hospitals are the expression of our cutting-edge translational science creating treatments and cures for the most devastating diseases.

“We are also pleased to announce that Microsoft will collaborate with UPMC in designing these ‘digital hospitals of the future.’ Building on our existing research collaboration with Microsoft and its Azure cloud platform, we will apply technology in ways that will transform what today is often a disjointed and needlessly complex experience for patients and clinicians,” said Romoff. “UPMC and Microsoft will have more to share in the coming months.”
The UPMC Vision and Rehabilitation Hospital, on the UPMC Mercy campus, is expected to open in 2020 to offer advanced clinical vision care. Clinicians and researchers at the new hospital will pursue promising new research for vision restoration and diseases of the eye, and offer technology-assisted rehabilitation services that restore mobility for patients with wide-ranging physical and cognitive challenges.The all-new hospitals will be situated on the campuses of UPMC’s Mercy, Presbyterian and Shadyside hospitals. Designs for the UPMC Heart and Transplant Hospital and the UPMC Hillman Cancer Hospital will be selected in an international design competition.

Patients of the UPMC Hillman Cancer Center, a name that is synonymous with unmatched excellence in cancer care, and the only National Cancer Institute-designated Comprehensive Cancer Center in the region, will receive specialized treatment in the new UPMC Hillman Cancer Hospital, located on the UPMC Shadyside campus. The facility is expected to open in 2022.

Building on UPMC’s legacy in organ transplantation, the UPMC Heart and Transplant Hospital in the heart of Oakland on the UPMC Presbyterian campus will provide the highest caliber organ transplantation and cardiac procedures available anywhere in the world.

“Tomorrow’s UPMC, we are confident, will not only be best-in-class,” said G. Nicholas Beckwith, III, chairperson, UPMC Board of Directors. “It will, in fact, have created a class virtually unto itself.”

The $2 billion investment is in addition to UPMC’s annual capital commitments of nearly $1 billion and will result in no increase in inpatient beds.

About UPMC’s Specialty Hospitals:

UPMC Heart and Transplant Hospital at UPMC Presbyterian

  • Home of Thomas E. Starzl, M.D., the “father of transplantation,” and these transplant firsts:
    • World’s first pediatric heart-liver transplant: 1984
    • World’s first heart-liver-kidney transplant: 1989
    • First medical center to discharge a patient on a ventricular assist device: 1990
  • Performed more than 19,500 total transplants and over 2,000 lung transplants, the most of any lung transplant program in the U.S.
  • One of the most experienced liver transplant programs in the country and a leader in living donor liver transplantation
  • Nationally ranked by U.S. News & World Report for cardiology and heart surgery for the last 10 years*
  • Location of the nation’s first LIVE (Less Invasive Ventricular Enhancement) surgery to repair the heart after severe heart attacks
  • Second center in the world to surpass 3,000 cardiothoracic transplants
  • One of only a few programs in the country with heart transplant recipients now nearing or beyond 30-years post-transplant

UPMC Hillman Cancer Hospital at UPMC Shadyside

  • Consistently ranked by U.S. News & World Report as having one of the best cancer programs in America*
  • The only nationally ranked cancer program in the region, and the only National Cancer Institute-designated Comprehensive Cancer Center in the region
  • Among the largest integrated community cancer networks in the U.S., providing world-class care and clinical research to more than 110,000 patients a year at over 60 locations
  • Allows patients to begin treatment plans and receive follow-up care after surgery in their own communities thanks to the UPMC Hillman Cancer Center network
  • Where patients seek comprehensive care, second opinions and clinical trials on rare cancers and the most challenging medical cases
  • Employs the latest innovative technologies, including intensity-modulated radiation therapy, treatments using RapidArc®, TrueBeam™ STx, CyberKnife®M6™, and PET–CT planning, which was pioneered by UPMC physicians

UPMC Vision and Rehabilitation Hospital at UPMC Mercy

  • UPMC Eye Center directed by world-renowned expert in vision therapies and developer of interventions, such as stem cell implantation, gene therapy, innovative pharmacologic approaches and the artificial retina
  • Leading research initiatives for vision restoration techniques, including age-related macular degeneration
  • Ranked one of the top ophthalmology programs in the U.S. by Ophthalmology Times for delivery of patient care
  • World-class ophthalmologists available to patients outside of Pittsburgh with real-time image transmission and video display through UPMC’s teleophthalmology program
  • Largest rehabilitation network in western Pennsylvania, and one of the largest in the U.S., treating 4,678 inpatients and 72,000 outpatients in the past year
  • Rehabilitation outcomes consistently better than national averages in the areas of patient independence, efficiency and discharge to the community
  • Implementing innovative early mobility initiatives for ICU patients to reduce the risk of delirium, muscle loss, ventilator-associated pneumonia and psychological distress
  • Clinical research to enable individuals with severe spinal cord injuries to control robotic arms with the brain and re-experience the sense of touch with brain-computer interfaces
  • Leading groundbreaking rehabilitation efforts for cancer patients, who need interdisciplinary rehabilitation because of the cancer itself or the treatment

Children’s Hospital of Pittsburgh of UPMC

  • Ranked on U.S. News & World Report’s Honor Roll of America’s Best Children’s Hospitals for eight consecutive years
  • Served patients and families from all 50 states and 50+ countries in the past five years with advanced specialty care
  • Nation’s first pediatric transplant center, performing more than 3,300 transplants
  • Heart Institute has one of the lowest overall four-year surgical mortality rates in the nation among all high-volume programs with a mortality rate under 2 percent
  • Heart Institute awarded a 3-Star rating by the Society of Thoracic Surgeons (2012-2016), one of only 11 programs to receive this distinction
  • First pediatric hospital in the nation recognized by HIMSS for its early adoption of electronic health records and technology to improve patient outcomes
  • Telemedicine consultation and care management programs provided globally with hospitals in Brazil, Colombia and Serbia, and nationally in Florida and Virginia

Western Psychiatric Institute and Clinic of UPMC

  • One of the top 12 hospitals in the nation for psychiatric care, according to U.S. News & World Report*
  • Leading recipient in National Institutes of Health psychiatry research funding
  • Only Center for Interventional Psychiatry and Behavioral Health Intensive Care Unit in the region
  • Award-winning specialty programs in child and adolescent bipolar disorders and adolescent suicide prevention
  • Nationally recognized by the Human Rights Campaign Foundation for LGBTQ health care equality
  • National pace-setter in the integration of behavioral health services in medical clinics
  • Centers for excellence in the diagnosis and treatment of addiction disorders
  • Ranked in the top 10 psychiatry resident training programs in the nation
  • Leading clinical psychology internship program in the country
  • One of the nation’s first and largest academic-affiliated telepsychiatry programs, averaging more than 12,000 consults a year

Magee-Womens Hospital of UPMC

  • Specialized expertise in women’s health across the lifespan, including prenatal and postnatal health, mid-life and menopausal services, and end-of-life care
  • One of the busiest obstetrics programs in the country, with nearly 10,000 babies born each year
  • Treats more than 1,500 seriously or critically ill babies each year in the highest volume neonatal intensive care unit in Pennsylvania and one of the largest in the country
  • Collaborates with Magee-Womens Research Institute, one of the largest research institutes in the U.S. devoted exclusively to women’s health research
  • One of the first teaching facilities recognized as a National Center of Excellence in Women’s Health by the U.S. Department of Health and Human Services
  • Offers women comprehensive and compassionate outpatient care for opioid addiction in a first-of-its-kind Pregnancy Recovery Center
  • One of the busiest clinical sites in the country for women’s cancer including nurses, doctors and support programs all focused on women’s cancer
  • Blend of clinical expertise and innovative research dedicated to breast cancer prevention and treatment ensures patients receive the most comprehensive breast care available

*U.S. News & World Report rankings are based on UPMC Presbyterian Shadyside data.

UPMC Acknowledged as ‘Top Performer’ in HAP Donate Life Hospital Challenge

The Hospital and Healthsystem Association of Pennsylvania (HAP), the Center for Organ Recovery & Education (CORE), Gift of Life Donor Program, and the Pennsylvania Department of Health (DOH) today announced the top hospitals and health systems of the 2017 HAP Donate Life Hospital Challenge.

The Pennsylvania Donate Life Hospital Challenge encourages Pennsylvania hospitals to increase organ donation awareness and designations within their hospital and community.
Hospitals are acknowledged for their efforts—the awareness and designation activities are captured on a scorecard for participating hospitals to achieve platinum, gold, silver, and bronze level recognitions.
A new designation level—titanium—was added to this year’s challenge. Pennsylvania is the first and only state to offer this designation. In order to reach the titanium level, hospitals engaged in unprecedented levels of clinical and community activities, aimed at encouraging new donor signups.
Each organ procurement organization region had five hospitals that reached the titanium level.

CORE Titanium Hospitals(western half of Pennsylvania):

Gift of Life Titanium Hospitals (eastern half of Pennsylvania):

  • Geisinger Medical Center
  • Hospital of the University of Pennsylvania
  • Reading Hospital
  • St. Luke’s Hospital – Bethlehem
  • Temple University Hospital

Nearly 100 hospitals and health systems across the state participated in the challenge, which ran from April 1 through August 31, 2017.

“This was a remarkable year for hospital participation in the Donate Life Hospital Challenge,” said Andy Carter, HAP president and CEO. “Pennsylvania’s hospital community knows that these donations help save lives and heal families. We commend participating hospitals for all they do to encourage Pennsylvanians to become organ donors, and thank the Department of Health, CORE, and Gift of Life for their ongoing partnership with this project.”
The collaborating organizations recognize the top hospitals and health systems in each organ procurement organization’s service area of the state.

The 2017 Top Performers of the Donate Life Hospital Challenge are:

CORE Top Performers
Top Health Systems:
First Place: UPMC Health System
Second Place: Conemaugh Health System
Third Place: Allegheny Health Network

Top Hospitals:
First Place: UPMC Presbyterian
Second Place: Conemaugh Memorial Medical Center
Third Place: Allegheny General Hospital

Gift of Life Top Performers
Top Health Systems:
First Place: Geisinger Health System
Second Place: PENN Medicine
Third Place: Einstein Health

Top Hospitals:
First Place: Geisinger Medical Center
Second Place: Temple University Hospital
Third Place: Hospital of the University of Pennsylvania

For the full list of hospital designations resulting from the challenge, and more information about the scoring process, visit HAP’s website.

Team from UPMC’s Division of Diabetes, Endocrinology, and Metabolism win $25,000 Pitt Innovation Challenge Award

Teams competed for funding during the fifth iteration of the Pitt Innovation Challenge Award (PInCh). Projects were awarded a total of $565,000 in funding a the PInCh final event on October 25, 2017. Seven teams competed in a poster session in which event attendees voted for the projects. Six teams then pitched their projects to a live judging panel and audience.

 

PINCH Team 2017

L to R: Steven Reis (CTSI director), Linda Siminerio, RN, PhD; Sandra Indocochea Sobel, MD; David Rometo, MD; Patrick McCarthy, RN, CDE. Not Pictured are Kristine Ruppert, DrPH; and Emily Timm, MS, RDN, LDN, BC-ADM, CDE.

The REMIT DM Team from UPMC’s Division of Diabetes, Endocrinology, and Metabolism was awarded $25,000 for their poster of a  protocol using continuous glucose monitors for temporary intensive insulin therapy at the time of type 2 diabetes diagnosis to induce beta cell restoration and diabetes remission.

7th Annual Acute Kidney Injury (AKI) Symposium Thursday, October 19, 2017

The 7th Annual AKI Symposium will be held Thursday, October 19 at the Starzl Biomedical Science Tower Conference Room S120.

UPMC experts across several divisions and departments will come together to discuss the latest in acute kidney injury research, further collaboration, patient advocacy, and education.

The symposium will include scientific presentations and posters from UPMC faculty as well as keynote speeches from guest faculty.

Registration begins at 7:30 am, and the conference adjourns at 4 p.m.

View the full agenda here.

 

2017 Congress of Neurological Surgeons Annual Meeting — live surgical presentation on Tuesday, October 10

For those attending the 2017 Congress of Neurological Surgeons Annual Meeting, be sure to visit the Demonstration Theater for a live surgical presentation on Tuesday, October 10, 2:00-2:30 p.m.:

Endoscopic and Endoscopic Assisted Skull Base Surgery

Operating Surgeon: Paul Gardner, MD, UPMC

Moderator: Garni Barkhoudarian, MD

This live surgical presentation is available to 2017 CNS attendees only.

UPMC-Developed Genetic Test Successfully Detects Some Asymptomatic Pancreatic Cancers

A genetic test developed at UPMC proved highly sensitive at determining which pancreatic cysts are most likely to be associated with one of the most aggressive types of pancreatic cancer, UPMC and University of Pittsburgh School of Medicine scientists reported in Gut, the journal of the British Society of Gastroenterology.

The successful results are a critical step toward a precision medicine approach to detecting and treating pancreatic cancer, which has one of the lowest survival rates of all cancers.

Pancreatic cysts — small pockets of fluid in the pancreas — are increasingly detected on medical scans by happenstance. For the most part, the cysts are benign. But because some can progress to pancreatic cancer, doctors must determine whether it is surgically necessary to remove the cysts.

“On the one hand, you never want to subject a patient to unneeded surgery. But survival rates for pancreatic cancer are much better if it is caught before symptoms arise, so you also don’t want to ignore an early warning sign,” said lead author Aatur D. Singhi, MD, PhD, a surgical pathologist in the UPMC Division of Anatomic Pathology. “This rapid, sensitive test will be useful in guiding physicians on which patients would most benefit from surgery.”

Singhi and his team at UPMC developed PancreaSeq®, which requires a small amount of fluid removed from the cyst to test for 10 different tumor genes associated with pancreatic cancer. It was the first such prospective study, testing pancreatic cysts before surgery, rather than analyzing cysts after surgery as had been done by previous efforts.

The study, funded in part by the Pancreatic Cancer Action Network and The National Pancreas Foundation, also was the first to evaluate a test that employed a more sensitive genetic sequencing method called next-generation sequencing and the first to be performed in a certified and accredited clinical laboratory as opposed to a research setting.

“This was important to us,” said Singhi. “If PancreaSeq is going to be used to make clinical decisions, then it needed to be evaluated in a clinical setting in real time, with all the pressures that go with a clinical diagnosis.”

In this analysis phase, the test was not intended to be used as the sole factor in determining whether to remove the cyst or not, so doctors relied on current guidelines when deciding on a course of treatment. A total of 595 patients were tested, and the team followed up with analysis of surgically removed cysts, available for 102 of the patients, to evaluate the accuracy of the test.

The study showed that with 100 percent accuracy, PancreaSeq correctly classified every patient in the evaluation group who had intraductal papillary mucinous neoplasm (IPMN) — a common precursor to pancreatic cancer — based on the presence of mutations in two genes, KRAS and GNAS. Furthermore, by analyzing mutations in three additional genes, the test also identified the cysts that would eventually progress to being cancerous lesions, also with 100 percent accuracy. test was less accurate for the less prevalent pancreatic cyst type called mucinous cystic neoplasm (MCN) — catching only 30 percent of the cases. Importantly, PancreaSeq did not identify any false positives in either cyst type, making it a highly specific test.

The researchers noted that the results could be biased by choice of which patients had their cysts surgically removed, but plan to monitor those who did not have their cysts removed to continue evaluation of the test’s reliability. An improved version of PancreaSeq that incorporates additional tumor genes associated with pancreatic cancer currently is undergoing rigorous clinical testing, according to Singhi. In the future, the team notes, clinical guidelines will need to be revisited to explore incorporating tests like PancreaSeq.

The PancreaSeq test currently is available to patients and ordered through UPMC.

Marina N. Nikiforova, MD, is the senior author on this study. Additional authors are Kevin McGrath, MD, Randall E. Brand, MD, Asif Khalid, MD, Herbert J. Zeh, MD, Jennifer S. Chennat, MD, Kenneth E. Fasanella, MD, Georgios I. Papachristou, MD, PhD, Adam Slivka, MD, PhD, David L. Bartlett, MD, Anil K. Dasyam, MD, Melissa Hogg, MD, Kenneth K. Lee, MD, James Wallis Marsh, MD, Sara E. Monaco, MD, N. Paul Ohori, MD, James F. Pingpank, MD, Allan Tsung, MD, Amer H. Zureikat, MD, and Abigail I. Wald, PhD, all of Pitt or UPMC, or both.

Page 1 of 82:1 2 3 4 »Last »